NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NewLink Genetics Corporation NLNK, Chipmos Technologies Ltd. IMOS, Helen of Troy Limited HELE, InterDigital, Inc. IDCC, Summit Therapeutics PLC SMMT, and Kornit Digital Ltd. KRNT, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
NLNK DOWNLOAD: http://Fundamental-Markets.com/register/?so=NLNK
IMOS DOWNLOAD: http://Fundamental-Markets.com/register/?so=IMOS
HELE DOWNLOAD: http://Fundamental-Markets.com/register/?so=HELE
IDCC DOWNLOAD: http://Fundamental-Markets.com/register/?so=IDCC
SMMT DOWNLOAD: http://Fundamental-Markets.com/register/?so=SMMT
KRNT DOWNLOAD: http://Fundamental-Markets.com/register/?so=KRNT
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine NewLink Genetics Corporation NLNK, Chipmos Technologies Ltd. IMOS, Helen of Troy Limited HELE, InterDigital, Inc. IDCC, Summit Therapeutics PLC SMMT, and Kornit Digital Ltd. KRNT on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
NEWLINK GENETICS CORPORATION (NLNK) REPORT OVERVIEW
NewLink Genetics' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, NewLink Genetics reported revenue of $10.10MM vs $12.70MM (down 20.51%) and basic earnings per share -$0.32 vs -$0.46. For the twelve months ended December 31st, 2017 vs December 31st, 2016, NewLink Genetics reported revenue of $28.71MM vs $35.77MM (down 19.73%) and basic earnings per share -$2.30 vs -$2.94. NewLink Genetics is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.72. The estimated EPS forecast for the next fiscal year is -$2.54 and is expected to report on March 7th, 2019.
To read the full NewLink Genetics Corporation (NLNK) report, download it here: http://Fundamental-Markets.com/register/?so=NLNK
-----------------------------------------
CHIPMOS TECHNOLOGIES LTD. (IMOS) REPORT OVERVIEW
Chipmos Technologies' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Chipmos Technologies reported revenue of $146.10MM vs $157.20MM (down 7.06%) and basic earnings per share $0.13 vs $0.20 (down 35.00%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Chipmos Technologies reported revenue of $567.52MM vs $605.96MM (down 6.34%) and basic earnings per share $1.01 vs $22.45 (down 95.50%). Chipmos Technologies is expected to report earnings on March 15th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.45.
To read the full Chipmos Technologies Ltd. (IMOS) report, download it here: http://Fundamental-Markets.com/register/?so=IMOS
-----------------------------------------
HELEN OF TROY LIMITED (HELE) REPORT OVERVIEW
Helen of Troy's Recent Financial Performance
For the three months ended November 30th, 2017 vs November 30th, 2016, Helen of Troy reported revenue of $453.05MM vs $444.41MM (up 1.94%) and basic earnings per share -$1.12 vs $2.10. For the twelve months ended February 28th, 2017 vs February 29th, 2016, Helen of Troy reported revenue of $1,537.22MM vs $1,545.70MM (down 0.55%) and basic earnings per share $5.11 vs $3.58 (up 42.74%). Helen of Troy is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending February 28th, 2018. The reported EPS for the same quarter last year was $1.62. The estimated EPS forecast for the next fiscal year is $6.93 and is expected to report on April 26th, 2018.
To read the full Helen of Troy Limited (HELE) report, download it here: http://Fundamental-Markets.com/register/?so=HELE
-----------------------------------------
INTERDIGITAL, INC. (IDCC) REPORT OVERVIEW
InterDigital's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, InterDigital reported revenue of $205.30MM vs $273.87MM (down 25.04%) and basic earnings per share $1.53 vs $3.94 (down 61.17%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, InterDigital reported revenue of $532.94MM vs $665.85MM (down 19.96%) and basic earnings per share $5.04 vs $8.95 (down 43.69%). InterDigital is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.93. The estimated EPS forecast for the next fiscal year is $2.56 and is expected to report on February 28th, 2019.
To read the full InterDigital, Inc. (IDCC) report, download it here: http://Fundamental-Markets.com/register/?so=IDCC
-----------------------------------------
SUMMIT THERAPEUTICS PLC (SMMT) REPORT OVERVIEW
Summit Therapeutics' Recent Financial Performance
For the three months ended October 31st, 2017 vs October 31st, 2016, Summit Therapeutics reported revenue of $2.29MM vs $0.70MM (up 226.32%) and basic earnings per share -$0.20 vs -$0.45. Summit Therapeutics is expected to report earnings on April 4th, 2018. The report will be for the fiscal period ending January 31st, 2018. The reported EPS for the same quarter last year was -$0.50. The estimated EPS forecast for the next fiscal year is -$3.13 and is expected to report on April 4th, 2018.
To read the full Summit Therapeutics PLC (SMMT) report, download it here: http://Fundamental-Markets.com/register/?so=SMMT
-----------------------------------------
KORNIT DIGITAL LTD. (KRNT) REPORT OVERVIEW
Kornit Digital's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Kornit Digital reported revenue of $28.45MM vs $30.92MM (down 8.00%) and basic earnings per share $0.00 vs $0.01. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Kornit Digital reported revenue of $108.69MM vs $86.41MM (up 25.80%) and basic earnings per share $0.03 vs $0.19 (down 84.21%). Kornit Digital is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.01. The estimated EPS forecast for the next fiscal year is $0.49 and is expected to report on February 12th, 2019.
To read the full Kornit Digital Ltd. (KRNT) report, download it here: http://Fundamental-Markets.com/register/?so=KRNT
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
